UK Markets closed

Sanofi - Contingent Value Right (GCVRZ)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
0.3799-0.00 (-0.03%)
At close: 3:59PM EDT
People also watch
  • SNY cranking up new highs!
  • SNY has up 20% in last two months, not bad. But need more clear path for growth of revenue.
  • SNY needs a clear strategy for its oncology drugs franchise to grow exponentially by acquiring fresh pipelines
  • SNY should be up today. FDA approved. What is happening? Any idea?
  • Any thoughts on why so many executives have left? Forced out or leaving on their own?
  • serious unbiased question? why the strong gain last few months ( even adj for annual dividend)? new trial drug? takeover target? acquisition? Something driving
  • MYMETICS (MYMX) got the goodies for this too!!!

    There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold
    Flu vaccines need to be administered annually. Sanofi's research team thinks they can...
  • Charles A. Henriques ( Global Popularity, A Bright Star In Pharma)
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area: Linkedin 1799 Connections

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
  • Received an alert this am about $GCVRZ from, you may want to take a look. Making money investing. John's collateral corollary: in order to get a loan you must first prove you don't need it.

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
  • Just saw this : Sanofi First Quarter Profit Rises Driven by Performance in Specialty HealthCare Division, Consumer Products

    BY Midnight Trader
    — 11:26 AM ET 04/28/2017
    Business net income totaled 1.80 billion euros ($1.97 billion), or 1.42 euros per share, compared with 1.72 billion euros, or 1.34 euros per share, in the same quarter a year earlier, results published by company on Friday showed. Net sales increased 11.1% to 8.65 billion euros, lifted by the acquisition of Boehringer Ingelheim's consumer healthcare business and full consolidation of Sanofi's European vaccine unit. At constant business structure and currencies, sales rose 3.5%, the company said.

    Genzyme sales increased 15.5% at constant currencies driven by multiple sclerosis products, while sales were down 7.7% at constant currencies at the diabetes and cardiovascular business, dragged down by lower demand for the company's diabetes products in the US, including Lantus for type-2 diabetes.

    Sales at the vaccines unit jumped 13.2% at constant structure and currencies led by children's products and at the consumer health care business they were 4.7% higher on the same basis.
    Stock goes up a whole 13 cents!!!!!!!!!!!!!!!
  • MYMETICS Corp. (MYMX)---under-the-radar sleeping gem

    Mymetics Corp. is an international biotechnology company successfully focused on developing virosome based vaccines to combat human infectious diseases.
  • has an alert for $GCVRZ. Did anyone happen to see it as well? Looking for some good positive information from the company! Sattinger's law: it works better if you plug it in. Investing day trading.

    Yuge Stocks: Trading Stocks and Making Money
    Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
  • SNY should buy Fitbit.
  • unbelievable 37000 a year for an eczema drug. sorry people preying on people who suffer from this doesn't make me want to be want to be an investor.
  • Comedy is tragedy plus time.

    Sanofi SA NYSE $SNY Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.6 In other words, the correlation coefficient of the other stocks
  • Sanofi still in acquisition mode. Flexion this time. Who's next?.. Mymetics Corp.?

  • Take the guess work out of finding tomorrow’s biggest gainers, ExplosiveOTC has proven time and again they deliver the best plays from across the markets.

  • Canadian side of Sanofi developed a revolutionary cholesterol lowering drug called Praluent. It can reverse damage done to the vascular system. The drug was just approved in Canada and there is the talk in the news that inventor might get a Noble prize for it. It could be huge.
  • Does anyone think Leukine has a chance at becoming something really, really big? The Alzheimer's tests look promising! But it's not getting mentioned as far as I can tell. Heck any drug manufacturer who has a cure for that disease should be a goldmine. I know it's years off from FDA approval (for this use), but still.
  • I also received an alert for $GCVRZ from , any ideas? Day trading investing. Tussman's law: nothing is as inevitable as a mistake whose time has come.

    Monsta Stocks: Trading Stocks and Making Money
    Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.